SHORT-TERM EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY ON RISK PREDICTORS FOR ARTERIOSCLEROSIS AMONG MEN WITH LATE-ONSET HYPOGONADISM: A CASE–CONTROL STUDY
暂无分享,去创建一个
K. Izumi | A. Mizokami | M. Namiki | K. Shigehara | H. Konaka | Y. Kadono | Yuki Kato | M. Iijima | Shohei Kawaguchi
[1] G. Doros,et al. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.
[2] Hun‐Sung Kim,et al. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. , 2018, Atherosclerosis.
[3] A. Dobs,et al. Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011–2012 National Health and Nutrition Examination Survey , 2018, The aging male : the official journal of the International Society for the Study of the Aging Male.
[4] M Namiki,et al. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study) , 2018, Andrologia.
[5] Y. Wang,et al. Testosterone replacement therapy improves health‐related quality of life for patients with late‐onset hypogonadism: a meta‐analysis of randomized controlled trials , 2017, Andrologia.
[6] Y. Takagi,et al. Role of the Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio in Predicting Serial Changes in the Lipid Component of Coronary Plaque. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[7] Y. Kitagawa,et al. The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.
[8] E. Rhoden,et al. Total testosterone levels are correlated to metabolic syndrome components , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.
[9] G. Doros,et al. Effects of intermission and resumption of long‐term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle‐aged and elderly men , 2016, Clinical endocrinology.
[10] S. Hisasue. Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management , 2015, International journal of urology : official journal of the Japanese Urological Association.
[11] S. Arver,et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men , 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.
[12] V. Mesch,et al. Association between testosterone levels and the metabolic syndrome in adult men , 2014, The aging male : the official journal of the International Society for the Study of the Aging Male.
[13] M. Rutter,et al. Late-onset hypogonadism and mortality in aging men. , 2014, The Journal of clinical endocrinology and metabolism.
[14] A. Traish,et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study , 2013, International journal of clinical practice.
[15] N. Smith,et al. Testosterone treatment and mortality in men with low testosterone levels. , 2012, The Journal of clinical endocrinology and metabolism.
[16] C. Vlachopoulos,et al. Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction: A Systematic Review and Meta-Analysis of Cohort Studies , 2012, Circulation. Cardiovascular quality and outcomes.
[17] C. Fraile,et al. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone , 2011, Andrologia.
[18] F. Akhras,et al. Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency , 2011, Andrologia.
[19] S. Kaplan,et al. Elevated high sensitivity C-reactive protein levels in aging men with low testosterone , 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.
[20] A. Traish,et al. Androgen deficiency and atherosclerosis: The lipid link. , 2009, Vascular pharmacology.
[21] C. Gazzaruso,et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. , 2008, Journal of the American College of Cardiology.
[22] H. Akaza,et al. Clinical Practice Manual for Late‐onset Hypogonadism Syndrome , 2008, International journal of urology : official journal of the Japanese Urological Association.
[23] M. Pfeffer,et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[24] F. Montorsi,et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. , 2006, European heart journal.
[25] P. Macfarlane,et al. Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2005, Circulation.
[26] D. Mertz. ["Atherosclerosis-index" (LDL/HDL): risk indicator in lipid metabolism disorders]. , 1980, Medizinische Klinik.
[27] Erasmus Mc,et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study , 2008, International Journal of Impotence Research.